>75%

Most men with an elevated PSA will have a prostate biopsy negative for clinically significant cancer.

The Challenge

You regularly grapple with the decision whether to proceed with biopsies in men with an elevated PSA. You know most of these men do not have clinically significant prostate cancer, but incomplete information keeps you from knowing who is truly at risk. And, under the traditional “biopsy all” approach, 75% of prostate biopsies are negative for clinically significant cancer. With stakes so high, you need the insights provided by the next generation of biomarker testing.

95%

NPV for Biopsy
Naïve Men

99%

NPV for Men with
Prior Negative Biopsy

The Solution

MyProstateScore 2.0 (MPS2) is the most comprehensive and flexible prostate cancer risk assessment tool, optimized for unrivaled accuracy for both previous negative biopsy and biopsy naïve patients, providing unparalleled insights to guide clinical decisions.

93%-99% NPV, depending on clinical context

Next-Generation Urine Biomarker Testing

Gauge - Your Results

Personalized Insights.

MPS2 improves on the foundational technology of MPS, a test recommended in the National Comprehensive Cancer Network® (NCCN®) Prostate Cancer Early Detection guidelines.

The MPS2 algorithm delivers optimized diagnostic accuracy and clinical flexibility for both patients under consideration for initial biopsy and those with a prior negative biopsy.

Order MPS2 as a biomarker-only test or inclusive of clinical risk factors, and receive a report indicating the individualized risk of clinically significant prostate cancer.

Proven Performance for Prior Negative Patients

Unrivaled Accuracy

Patients with a history of a negative prostate biopsy who present with persistently elevated or increasing PSA results, and/or suspicious DRE findings, present a unique clinical challenge.

Historically, biomarker tests and risk assessment tools have suffered from an absence of data or diminished performance in this complex repeat biopsy population.

Lynx Dx has developed MyProstateScore 2.0 (MPS2), which combines the predictive power of 18 urine biomarkers with those clinical factors most relevant to repeat biopsy patients to produce the first biomarker test with 99% NPV for the prediction of Grade Group ≥ 2 prostate cancer in patients with a previous negative biopsy.

18 Unique Gene Transcripts

MPS2 analyzes 18 unique gene transcripts within models shown to predict clinically significant cancer across a variety of patient cohorts.

T2:ERG
SCHLAP1
OR51E2
APOC1
PCAT14
CAMKK2
PCA3
NKAIN1
B3GNT6

18 Biomarkers

TFF3
SPON2
PCGEM1
TRGV9
TMSB15A
ERG
KLK3
KLK4
HOXC6

T2:ERG
SCHLAP1
OR51E2
APOC1
PCAT14
CAMKK2
PCA3
NKAIN1
B3GNT6

18 Biomarkers

TFF3
SPON2
PCGEM1
TRGV9
TMSB15A
ERG
KLK3
KLK4
HOXC6

Urine Sample icon

Simple Collection

Report icon

Clear Results

Research and Publications

Lynx Dx and its research partners at the University of Michigan are dedicated to the highest quality of research excellence, including the breakthrough discovery of the novel T2:ERG gene fusion for which Dr. Arul Chinnaiyan was awarded the 2022 Sjoberg Prize.